对此，该泼的冷水还是要泼的，到目前为止，基于调节性T细胞产生的上市药品数量是：0。 本文来自微信公众号：一个生物狗的科普小园，作者：Y博的科普园，题图来自：AI生成 2025年诺贝尔生理学与医学奖给了调节性T细胞的发现。大概是由于该奖是在与疾病过度相关的免疫学 领域，而且也在包括肿瘤、自身免疫疾病等方向的研究中扮演关键角色，不少人对该奖成果的应用充满 期待。 不过，网络上的热度往往跑得比科学还快。一些文章宣称"未来XX病有望被治愈"，甚至有人蹭热点声 称某维生素影响调节性T细胞，能起到XX作用。 它们都不是基于调节性T细胞的研究。 一个都没有。 尽管有些靶向或利用调节性T细胞的药物、疗法在临床试验阶段，预计的上市时间也会是好几年后—— 能否成功也有巨大的不确定性。 参考获奖者之一，坂口志文获奖消息公布后，在日本大阪大学新闻发布会上的小插曲。日本首相在发布 会中间打电话祝贺，其中问到研究什么时候能治好癌症，坂口志文的回答是可能20年后，自己那会儿还 在不在都不确定。 坂口志文与另一位获奖者Ransdell都创建了将调节性T细胞用于疾病治疗的生物技术公司。但是这些公 司与调节性T细胞相关的产品都处于早期研发阶段。 ...

日本人在免疫领域获得诺贝尔奖的是1987年的利根川进、2018年的本庶佑，坂口志文是第三 人。在他们背后，还有许多研究者一直在世界前沿取得诺贝尔奖级的成果…… 研究体内入侵病原体的免疫机制，被称为日本的"家传技艺"。不仅是2025年诺贝尔生理学或 医学奖得主坂口志文，2018年获奖的京都大学特聘教授本庶佑也是免疫研究领域的第一人。 虽然日本在诺贝尔奖上曾一度沉寂，但研究者队伍依然雄厚，不断产出引领世界的优秀成 果。 坂口志文在母校京都大学学习时，并非专攻免疫学。他曾中途退学进入爱知县癌症中心磨练 研究技能，并在1980年代崭露头角。他发现了一个现象，去除特定免疫细胞反而会激活免疫 反应，进而引发自身免疫疾病。 当时，坂口志文并未被专业人士重视。然而，他依然按照自己的信念坚持不懈地进行研究， 陆续发表了成为调节性T细胞证据的重要成果，并获得了世界认可。 大阪大学特任教授坂口志文在确定获得诺贝尔生理学或医学奖后举行记者会（10月6日，大阪府吹田市） 后来，他的研究还揭示了调节性T细胞与自身免疫疾病和癌症的关系。致力于开发被期待 为"第五种癌症治疗"的光免疫疗法的乐天医疗（Rakuten Medical）公司，在2 ...

Core Viewpoint - The article announces the launch of the open-access journal "Immunity & Inflammation," focusing on significant scientific issues and advancements in the fields of immunology and inflammation [2][4]. Group 1: Journal Overview - "Immunity & Inflammation" is co-edited by prominent figures in immunology, including Nobel laureates and leading researchers from various countries [2][5]. - The journal aims to bridge foundational insights with medical innovations, publishing high-quality original research, reviews, and highlights across basic, translational, and clinical research [6]. Group 2: Research Focus - The journal particularly welcomes studies exploring the dual nature of inflammation, inflammation-driven diseases, novel anti-inflammatory interventions, and groundbreaking findings in immune regulation [6]. - It encourages interdisciplinary research, including the use of artificial intelligence and digital health technologies, and aims to establish new standards in relevant research and practice areas [6]. Group 3: Editorial Commitment - The journal is committed to maintaining the highest standards of scientific ethics, integrity, transparency, and reproducibility [6][7]. - It invites global scientific communities to collaborate and contribute to making "Immunity & Inflammation" a vibrant and impactful academic platform [7].

Group 1 - The article introduces Professor Song Zhenju, who holds multiple prestigious positions in emergency medicine and clinical research, including Director of the Emergency Department at Fudan University Zhongshan Hospital and Vice President of the same hospital [1] - Professor Song has led numerous national and provincial research projects, published extensively in high-impact journals, and holds multiple patents, indicating a strong research background and contributions to the field [1] Group 2 - The research directions focus on Acute Respiratory Distress Syndrome (ARDS) mechanisms and interventions, organ damage from sepsis, and mechanisms and interventions for acute poisoning [6] Group 3 - Recruitment is open for postdoctoral positions in fields such as Clinical Medicine, Life Sciences, Biology, Biomedical Engineering, and Pharmacy [3] - Candidates must be under 35 years old, have a strong academic background, and have published at least one SCI paper [5] Group 4 - Compensation will follow national and Fudan University standards, with additional rewards for outstanding performance during the contract period [7] Group 5 - Applicants are required to submit a detailed CV, proof of doctoral degree, and 1-3 representative papers [8] - Contact information for applications is provided, with specific instructions for email subject lines [9][10]

Group 1 - Sanofi is acquiring Blueprint Medicines Corp for $9.1 billion in equity value, enhancing its pipeline in rare immune diseases [1][2] - The acquisition price is set at $129 per share, representing a 27% premium over Blueprint's closing price last Friday [1] - Blueprint shareholders will receive a contingent value right (CVR) worth an additional $2 to $4 per share if the BLU-808 drug meets certain development and regulatory milestones [1] Group 2 - This acquisition reflects Sanofi's ambition to establish a leadership position in immunology, following a previous announcement to acquire Dren Bio, Inc. for up to $1.9 billion [1] - Blueprint Medicines has a strong clinical network among specialists and a pipeline that includes several immunotherapy candidates [2] - The total value of the transaction, including potential CVR payments, is approximately $9.5 billion, with Sanofi expecting the deal to close in the third quarter without significant impact on its 2025 financial guidance [2]